Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $36.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the stock. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. HC Wainwright boosted their price target on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Down 1.6%

NASDAQ OMER opened at $13.26 on Tuesday. The stock has a market cap of $954.72 million, a PE ratio of -26.52 and a beta of 2.53. The business has a 50 day moving average price of $11.47 and a two-hundred day moving average price of $10.57. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65.

Omeros (NASDAQ:OMER) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, beating the consensus estimate of ($0.55) by $3.69. Sell-side analysts anticipate that Omeros will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OMER. Farther Finance Advisors LLC boosted its holdings in shares of Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares during the period. State of Wyoming bought a new stake in shares of Omeros during the 4th quarter valued at about $25,000. AQR Capital Management LLC raised its stake in Omeros by 7.2% during the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,532 shares during the period. ProShare Advisors LLC raised its stake in Omeros by 12.1% during the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 1,637 shares during the period. Finally, Cerity Partners LLC lifted its holdings in Omeros by 6.1% in the fourth quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 1,750 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.